Dermata Therapeutics Q2 2026 Earnings Report

Dermata Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.55
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Dermata Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Dermata Therapeutics Announcement Details

• Quarter: Q2 2026
• Date: 8/18/2026
• Time: Before Market Opens
• Conference Call Date: Friday, August 14, 2026
• Conference Call Time: 4:00PM ET

Dermata Therapeutics (NASDAQ:DRMA) is a clinical-stage immunodermatology company dedicated to developing novel small-molecule therapies for inflammatory skin disorders. The company’s lead clinical candidate, DMVT-502, is being evaluated in atopic dermatitis, while DMVT-505 is in development for vitiligo. In addition to these programs, Dermata advances preclinical assets targeting other indications such as alopecia areata.

At the core of Dermata’s approach is a proprietary drug discovery platform that combines structure-based design, medicinal chemistry and innovative formulation techniques. This integrated platform enables the identification and optimization of both topical and oral small molecules that modulate key intracellular signaling pathways involved in skin inflammation.

Headquartered in Cambridge, Massachusetts, Dermata collaborates with academic institutions and contract research organizations across the United States and Europe to conduct translational studies and clinical trials. The company’s network of clinical sites supports the efficient advancement of its pipeline from preclinical research through clinical development.

Dermata’s management team brings together expertise in pharmaceutical research and development, regulatory affairs and dermatology commercialization. With a focus on addressing unmet needs in skin health, the company aims to deliver best-in-class therapies that improve outcomes and quality of life for patients living with inflammatory skin diseases.